N-[4-[2-(3,4-dihydroxyphenyl)ethyl]phenyl]-2-hydroxy-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-[2-(3,4-dihydroxyphenyl)ethyl]phenyl]-2-hydroxy-benzamide
• 英文别名: N-{4-[2-(3,4-Dihydroxy-phenyl)-ethyl]-phenyl}-2-hydroxy-benzamide；N-[4-[2-(3,4-dihydroxyphenyl)ethyl]phenyl]-2-hydroxybenzamide
• 化学式: C₂₁H₁₉NO₄
• 分子量: 349.386
• InChiKey: ZKKKHQQIZGSURN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  89.8
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(4-硝基苯基)乙酰氯 在 palladium on activated charcoal sodium hydroxide 、 三氯化铝 、 硫酸 、 氢气 、 三溴化硼 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-[4-[2-(3,4-dihydroxyphenyl)ethyl]phenyl]-2-hydroxy-benzamide
  参考文献：
  名称：

  Catechol based inhibitors of 15-lipoxygenase

  摘要：

  A potent 15-lipoxygenase (15-LO) inhibitor, compound 6, was identified by mass screening the Parke-Davis compound portfolio. The active moiety of compound 6 was determined to be the catechol functionality. Additional analogs were prepared and analyzed for inhibitory activity against 5-, 12-, and 15-lipoxygenase.

  DOI：

  10.1016/0960-894x(95)00565-b

文献信息

• (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0221346B1

  公开（公告）日：1991-01-30
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• Method and Composition for Treating Inflammatory Disorders
  申请人：Meda AB

  公开号：US20160166508A1

  公开（公告）日：2016-06-16

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• US4939133A
  申请人：——

  公开号：US4939133A

  公开（公告）日：1990-07-03